Dashboard
Manage Tickers

ADAG Adagene Inc.

Nasdaq adagene.com


$ 1.76 $ -0.02 (-1.12 %)    

Friday, 17-Oct-2025 15:59:50 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 604.92 $ 3.94 (0.66 %)
DIA $ 461.73 $ 2.22 (0.48 %)
SPY $ 665.28 $ 3.75 (0.57 %)
TLT $ 91.09 $ -0.14 (-0.15 %)
GLD $ 391.28 $ -7.46 (-1.88 %)
$ 1.76
$ 1.84
$ 1.75 x 3,977
$ 1.85 x 1,518
$ 1.76 - $ 1.85
$ 1.33 - $ 3.16
25,827
na
82.91M
$ 0.67
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

lucid-capital-markets-initiates-coverage-on-adagene-with-buy-rating-announces-price-target-of-9
LUCID CAPITAL MARKETS Initiates Coverage O...
09/18/2025 12:21:21

LUCID CAPITAL MARKETS analyst Christopher Liu initiates coverage on Adagene (NASDAQ:ADAG) with a Buy rating and announces Pr...

Core News & Articles
Adagene Expands Announces Amendment Ti 202...
09/16/2025 12:07:09

Core News & Articles
12 Health Care Stocks Moving In Tuesday's ...
09/09/2025 17:06:26

adagenes-masked-ctla-4-antibody-adg126-to-be-highlighted-in-dual-oral-presentations-at-2025-csco-meeting-data-highlights-include-phase-1b2-results-in-mss-crc-and-combination-with-pembrolizumab
Adagene's Masked CTLA-4 Antibody ADG126 To...
09/05/2025 14:01:59

hc-wainwright--co-maintains-buy-on-adagene-lowers-price-target-to-7
HC Wainwright & Co. Maintains Buy on Adage...
08/15/2025 11:29:38

HC Wainwright & Co. analyst Arthur He maintains Adagene (NASDAQ:ADAG) with a Buy and lowers the price target from $8 to $7.

Core News & Articles
12 Health Care Stocks Moving In Thursday's...
08/14/2025 17:06:18

adagene-h1-adj-eps-019-beats-034-estimate
Adagene H1 Adj. EPS $(0.19) Beats $(0.34) ...
08/12/2025 20:24:29

Adagene (NASDAQ:ADAG) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0.34) by 44...

this-palvella-therapeutics-analyst-begins-coverage-on-a-bullish-note-here-are-top-5-initiations-for-wednesday
This Palvella Therapeutics Analyst Begins ...
08/06/2025 12:10:52

leerink-partners-initiates-coverage-on-adagene-with-outperform-rating-announces-price-target-of-7
Leerink Partners Initiates Coverage On Ada...
08/06/2025 12:02:17

Leerink Partners analyst Daina Graybosch initiates coverage on Adagene (NASDAQ:ADAG) with a Outperform rating and announces ...

adagene-has-received-written-feedback-from-the-fda-on-its-clinical-development-plan-to-evaluate-muzastotug-adg126-in-combination-with-mercks-keytruda-for-microsatellite-stable-colorectal-cancer-patients-enrollment-in-phase-2-to-start-in-2h-2025
Adagene Has Received Written Feedback From...
07/15/2025 11:08:08

adagene-partners-with-conjugatebio-to-advance-bispecific-antibody-drug-conjugates-using-proprietary-antibody
Adagene Partners With ConjugateBio To Adva...
07/08/2025 11:02:21

sanofi-invests-up-to-25m-in-adagene-to-advance-cancer-drug-trials
Sanofi Invests Up to $25M in Adagene to Ad...
07/01/2025 11:09:51

Adagene Inc. ("Adagene or the Company") (NASDAQ:ADAG), a company transforming the discovery and development of novel an...

adagene-files-for-offering-of-up-to-100m-american-depositary-shares-representing-ordinary-shares
Adagene Files For Offering Of Up To $100M ...
05/30/2025 21:12:18

 - SEC Filing

adagene-reveals--updated-data-from-phase-1b2-study-of-muzastotug-in-combination-with-keytruda-in-colorectal-cancer-at-the-american-society-of-clinical-oncology--annual-meeting
Adagene Reveals Updated Data from Phase 1...
05/22/2025 21:14:19

adagene-files-for-mixed-shelf-of-up-to-200m
Adagene Files For Mixed Shelf Of Up To $200M
05/09/2025 20:38:49

-SEC Filing

hc-wainwright--co-reiterates-buy-on-adagene-maintains-8-price-target
HC Wainwright & Co. Reiterates Buy on Adag...
04/03/2025 10:53:46

HC Wainwright & Co. analyst Arthur He reiterates Adagene (NASDAQ:ADAG) with a Buy and maintains $8 price target.

adagene-fy24-adj-eps-051-vs-021-yoy-revenues-103204
Adagene FY24 Adj. EPS $(0.51) vs $(0.21) Y...
03/24/2025 12:05:55

adagene-announces-investigator-initiated-phase-2-trial-for-neoadjuvant-muzastotug-in-colorectal-cancer
Adagene Announces Investigator Initiated P...
02/27/2025 13:18:51

- Trial to begin enrolling in April; expected primary completion in mid-2027 -- Primary study endpoint of rate of major patholo...

hc-wainwright--co-maintains-buy-on-adagene-raises-price-target-to-8
HC Wainwright & Co. Maintains Buy on Adage...
01/27/2025 12:52:14

HC Wainwright & Co. analyst Arthur He maintains Adagene (NASDAQ:ADAG) with a Buy and raises the price target from $5 to $8.

adagene-announces-updated-data-from-phase-1b2-study-of-muzastotug-in-combination-with-keytruda-showing-overall-33-overall-response-rate
Adagene Announces Updated Data From Phase ...
01/27/2025 12:04:31

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION